Evogene Ltd.

NASDAQ: EVGN · Real-Time Price · USD
1.32
-0.04 (-2.94%)
At close: Aug 15, 2025, 11:26 AM

Evogene Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
8.51M 5.64M 1.68M 930K
Cost of Revenue
2.68M 4.24M 909K 767K
Gross Profit
5.83M 1.4M 766K 163K
Operating Income
-22.21M -26.39M -26.94M -30.95M
Interest Income
957K 1.25M 516K 1.94M
Pretax Income
-18.05M -25.99M -29.75M -30.43M
Net Income
-16.48M -23.88M -26.64M -27.79M
Selling & General & Admin
10.87M 9.68M 10.41M 7.25M
Research & Development
16.65M 18.11M 20.79M 23.86M
Other Expenses
524K n/a -3.5M n/a
Operating Expenses
28.04M 27.79M 27.71M 31.12M
Interest Expense
124K 171K 3.33M 1.41M
Selling & Marketing Expenses
822K 1.01M 3.93M n/a
Cost & Expenses
30.72M 32.03M 28.62M 31.88M
Income Tax Expense
9K -33K 90K 13K
Shares Outstanding (Basic)
5.7M 4.57M 4.12M 41.01M
Shares Outstanding (Diluted)
5.7M 4.57M 4.12M 41.01M
EPS (Basic)
-2.89 -5.23 -6.46 -0.68
EPS (Diluted)
-2.89 -5.23 -6.46 -0.68
EBITDA
-15.48M -23.2M -26.93M -27.8M
EBIT
-17.98M -25.87M -29.59M -30.03M
Depreciation & Amortization
2.5M 2.61M 2.58M 2.23M